Literature DB >> 1629903

High prevalence of stably derepressed class-I beta-lactamase expression in multiresistant clinical isolates of Enterobacter cloacae from Greek hospitals.

E Tzelepi1, L S Tzouvelekis, A C Vatopoulos, A F Mentis, A Tsakris, N J Legakis.   

Abstract

Susceptibilities to cefotaxime (Ctx) and ceftazidime (Caz) were examined for 90 recent clinical isolates of Enterobacter cloacae from Greek hospitals. Most (68%) of the isolates were resistant to both drugs, and all were resistant to cefoxitin. beta-Lactamase activities against cephaloridine in crude extracts from Ctx-Caz-resistant isolates were high, irrespective of whether or not the cells were grown with cefoxitin as an inducer of the chromosomal beta-lactamase, indicating stable derepression of the gene for the enzyme. On the other hand, double disk antagonism tests showed that all the Ctx-Caz-sensitive isolates possessed inducible expression of this beta-lactamase. Iso-electric focusing revealed the presence of five forms of the chromosomal beta-lactamase, randomly distributed amongst the Ctx-Caz-resistant and -sensitive isolates. Plasmid-mediated beta-lactamases of TEM and PSE types also were found in many isolates. These data indicate that the extremely high prevalence of Ctx-Caz-resistant E. cloacae isolates in Greek hospitals is attributed to the dissemination of mutants which constitutively overproduce the class-I chromosomal beta-lactamase. Over 90% of these isolates exhibited cross-resistance to aminoglycosides, suggesting the accumulation of unrelated antibiotic resistance mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1629903     DOI: 10.1099/00222615-37-2-91

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  11 in total

1.  Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.

Authors:  E Tzelepi; P Giakkoupi; D Sofianou; V Loukova; A Kemeroglou; A Tsakris
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis; N J Legakis
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

3.  Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain.

Authors:  K Colom; A Fdz-Aranguiz; E Suinaga; R Cisterna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

4.  Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be.

Authors:  L S Tzouvelekis; M Gazouli; E E Prinarakis; E Tzelepi; N J Legakis
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 5.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 6.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  Outbreak of infections caused by Enterobacter cloacae producing the integron-associated beta-lactamase IBC-1 in a neonatal intensive care unit of a Greek hospital.

Authors:  Georgia Kartali; Eva Tzelepi; Spyros Pournaras; Constantina Kontopoulou; Fanourios Kontos; Danai Sofianou; Antonios N Maniatis; Athanassios Tsakris
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 8.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Outbreak of infection caused by Enterobacter cloacae producing the novel VEB-3 beta-lactamase in China.

Authors:  Xiaofei Jiang; Yuxing Ni; Yanqun Jiang; Feiyi Yuan; Lizhong Han; Ming Li; Hong Liu; Li Yang; Yuan Lu
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

10.  Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals.

Authors:  D Gianneli; E Tzelepi; L S Tzouvelekis; A F Mentis; C Nikolopoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.